EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging therapies for eosinophilic esophagitis

Patrick D Meek iD, Brian Hemstreet iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2783 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Patrick D Meek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Deglutition Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus that is quickly becoming a more recognized cause of esophageal dysfunction and dysphagia. The cause of EoE is thought to be due to an inflammatory response triggered by exposure to dietary or environmental antigens. Symptoms may be progressive and include reflux, nausea, vomiting, dysphagia, and reduction in quality of life. Both children and adults may be affected. Initial treatments for EoE have focused on elimination diets to potentially identify and remove dietary triggers, acid suppression with proton pump inhibitors, and topical delivery of orally administered swallowed corticosteroids. These therapies are often ineffective in a large proportion of patients, leading to exploration of other approaches by focusing on cytokines involved in the inflammatory response. Most recently, dupilumab, a monoclonal antibody targeting IL‐4 received approval for use in patients aged 12 years or older with EoE. Use of dupilumab has seen favorable improvements in disease progression and symptoms with chronic use. Other therapies targeting IL‐5, such as mepolizumab, reslizumab, and benralizumab are currently being studied for use in EoE. Therapies targeting other key inflammatory mediators in EoE, such as Siglec‐8 (lirentelimab), IL‐13 (cendakimab), and the sphingosine 1‐phosphate receptor (etrasimod) are currently being evaluated in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisDeglutition DisordersAdultChildHumansQuality of LifeAdrenal Cortex HormonesProton Pump Inhibitors

Stichwörter der Autor:innen

corticosteroidsesophagitisesosinophilicinterleukinsproton pump inhibitorstopical

Substanzen

Adrenal Cortex HormonesProton Pump Inhibitors

Autor:innen und Institutionen

  • Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
  • University of Colorado, Department of Clinical Pharmacy, Aurora, Colorado, USA.

ORCID-Profile: Patrick D Meek, Brian Hemstreet

Zitieren

APA

Meek, P. D., & Hemstreet, B. (2023). Emerging therapies for eosinophilic esophagitis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2783

Vancouver

Meek PD, Hemstreet B. Emerging therapies for eosinophilic esophagitis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2783

BibTeX
@article{Meek2023,
  author = {Meek, Patrick D and Hemstreet, Brian},
  title = {Emerging therapies for eosinophilic esophagitis},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2783}
}
Kostenlos starten →